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Claspin is required for the phosphorylation and activation of the
Chk1 protein kinase by ATR during DNA replication and in
response to DNA damage. This checkpoint pathway plays a critical
role in the resistance of cells to genotoxic stress. Here, we show that
human Claspin is cleaved by caspase-7 during the initiation of apo-
ptosis. In cells, induction of DNA damage by etoposide at first pro-
duced rapid phosphorylation of Chk1 at a site targeted by ATR.
Subsequently, etoposide caused activation of caspase-7, cleavage of
Claspin, and dephosphorylation of Chk1. In apoptotic cell extracts,
Claspin was cleaved by caspase-7 at a single aspartate residue into a
large N-terminal fragment and a smaller C-terminal fragment that
contain different functional domains. The large N-terminal frag-
ment was heavily phosphorylated in a human cell-free system in
response to double-stranded DNA oligonucleotides, and this frag-
ment retained Chk1 binding activity. In contrast, the smaller C-ter-
minal fragment did not bind Chk1, but did associate with DNA and
inhibited the DNA-dependent phosphorylation of Chk1 associated
with its activation. These results indicate that cleavage of Claspin by
caspase-7 inactivates the Chk1 signaling pathway. This mechanism
may regulate the balance between cell cycle arrest and induction of
apoptosis during the response to genotoxic stress.
Eukaryotic cells maintain genomic integrity by monitoring DNA for
damage or incomplete replication. In the event of aberrant structures
being detected, checkpoint mechanisms are activated that delay cell
cycle progression and that allow the damage to be repaired or replica-
tion to be completed (1). DNA damage can also initiate pathways lead-
ing to apoptosis and the removal of a damaged cell from a tissue (2). The
balance between cell cycle arrest and damage repair on one hand and
the initiation of apoptosis on the other determines the survival of indi-
vidual cells and the maintenance of genomic stability. Defects in the
balance between these responses may lead to hypersensitivity to DNA
damage or, conversely, to resistance to apoptosis and maintenance of
genomic defects, which characterize cancer cells. Furthermore, the
response of cells to anticancer treatments that damageDNAmay deter-
mine therapeutic outcomes (3, 4).
The Chk1 protein kinase is a central component of a conserved
checkpoint pathway activated by DNA damage or replication stress (5).
Once activated, Chk1 inhibits Cdc25 phosphatases, which control
inhibitory phosphorylation sites on cyclin-dependent protein kinases,
critical regulators of cell cycle transitions (3, 6). In vertebrates, activa-
tion of Chk1 in response to DNA damage or replication arrest induced
byUV light or hydroxyurea involves the ATR (ATM- and Rad3-related)
kinase. ATR directly phosphorylates Chk1 at serines 317 and 345 in
vitro, and phosphorylation of these sites in human cells in response to
UV light and hydroxyurea is ATR-dependent (7, 8). Chk1 also under-
goes autophosphorylation associated with its full activation (9). Defects
in the ATR/Chk1 pathway have been implicated in the loss of genomic
stability and in the development of cancer (3, 7, 10). Conversely, genetic
ablation of ATR (11, 12) or Chk1 (7, 10, 13, 14) or their inhibition by
kinase inhibitors (15–17) sensitizes cells to DNA damage and induces
cell death, showing that this checkpoint pathway plays a critical role in
determining cell survival following genotoxic stress.
Phosphorylation and activation of Chk1 by ATR require Claspin, a
protein first identified by co-purification with Chk1 from Xenopus egg
extracts (18) and subsequently shown to be involved in Chk1 activation
in human cells (19, 20). Mrc1, an apparent homolog in yeast, is instead
involved in activation of the Chk2 kinase homologs, Rad53 (Saccharo-
myces cerevisiae) and Cds1 (Schizosaccharomyces pombe), in response
to DNA replication stress (21, 22). In vertebrates, Claspin may act as a
scaffolding protein that brings together ATR and Chk1 (18, 23). Claspin
interacts with chromatin during S phase, indicating that it may also act
as a sensor of DNA replication (24, 25). Although Claspin has a DNA-
binding motif in its N-terminal half (26), similar to Mrc1 (27), it is not
clear if this direct interaction with DNA occurs in cells. The association
of Claspin with chromatin during S phase involves the pre-replication
complex and Cdc45 (24). Claspin has also been reported to associate
with ATR and the Rad9-Rad1-Hus1 complex (19) and with BRCA1 (20)
in human cells.
The interaction of Claspin with Chk1 requires two phosphorylation
sites in a tandem motif that lies within the Chk1-binding domain (28,
29), which interacts with the kinase domain of Chk1 (30). Phosphoryl-
ation of these two sites is ATR-dependent, but may not be directly
catalyzed by ATR (20, 28, 29). The interaction of Claspin with chroma-
tin inXenopus egg extracts is inhibited by phosphorylation by theXeno-
pus Polo-like kinase Plx1, which inactivates the checkpoint as part of an
adaptive response (31). In cultured human cells, depletion of Claspin by
small interfering RNA increases sensitivity to genotoxic stress and pro-
motes cell death (19, 20). Claspin may therefore be pivotal in determin-
ing the balance between cell cycle control and induction of cell death.
Here, we report that human Claspin is cleaved into two functional
domains during the initiation of apoptosis by caspase-7 both in cell-free
systems and in intact cells. Using a human cell-free system in which the
checkpoint pathway is activated by double-stranded oligonucleotides,
we show that the larger N-terminal fragment retains Chk1 binding
activity, whereas the smaller C-terminal fragment associates with DNA.
This smaller fragment has a dominant inhibitory effect on Chk1 phos-
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phorylation associated with its activation. In human cells, cleavage of
Claspin by caspase-7 following genotoxic stress and the subsequent loss
of Chk1 phosphorylation may switch the cellular response from cell
cycle arrest to apoptosis.
MATERIALS ANDMETHODS
Claspin Proteins—Human full-length Claspin and Claspin-(679–
1332) were produced as described previously (29). Other Claspin frag-
ments were generated in pcDNA3.2-DEST (Invitrogen) by site-directed
mutagenesis to create stop codons or restriction digestion at convenient
restriction sites and subcloning into a pET vector (Novagen). Claspin
mutants D841A, D1031A, D1072A, D1085A, and D1158A were gener-
ated by site-directed mutagenesis. His6-tagged 35S-labeled Claspin pro-
teins were expressed from pET vectors in reticulocyte lysate using the
TNT Quick coupled transcription/translation system (Promega)
according to the manufacturer’s protocol. The His6-tagged C-terminal
fragment (amino acids 1073–1332) was expressed in Escherichia coli;
purified on nickel-nitrilotriacetic acid beads (Qiagen Inc.); desalted on a
PD10 column; and stored at70 °C in 25 mM Hepes (pH 7.5), 150 mM
NaCl, 1mM dithiothreitol, and protease inhibitors (1g/ml aprotinin, 1
g/ml leupeptin, 1 g/ml pepstatin A, 0.1 mM phenylmethylsulfonyl
fluoride, 1 mM EDTA, 1 g/ml chymostatin, and 1 mM benzamidine).
Antibodies—Antibodies against human Chk1 used for immunopre-
cipitation were raised in sheep inoculated with glutathione S-transfer-
ase-Chk1 (32) and purified against the protein coupled to Reacti-Gel
beads (Pierce). A rabbit polyclonal antibody against the C-terminal
region of human Claspin was raised against a peptide (CKESSKSQKI-
PEKDSD) corresponding to amino acids 1297–1311 of Claspin with the
addition of Cys for coupling the peptide. The commercial antibodies
used were as follows: rabbit anti-Claspin (Ab73, Bethyl Laboratories);
goat anti-ATR (FRP1; N-19), mouse monoclonal anti-Chk1 (for West-
ern blotting; G4), rabbit anti-caspase-3 (for Western blotting; H-277),
goat anti-caspase-3 p11 (for immunodepletions; K-19), goat anti-
caspase-7 p20 (N-17), and rabbit anti-caspase-9 (for depletions; H-83)
(Santa Cruz Biotechnology, Inc.); rabbit anti-phospho-Ser345/Ser317/
Ser296 Chk1 (Cell Signaling Technology); rabbit anti-poly(ADP-ribose)
polymerase (PARP3; AHP427, Serotec); and mouse monoclonal anti-
caspase-8 and rabbit anti-caspase-9 (for Western blotting) (Pharmin-
gen). The secondary horseradish peroxidase-conjugated antibodies
used were anti-mouse immunoglobulin (Amersham Biosciences), anti-
rabbit immunoglobulin (Bio-Rad), and anti-goat immunoglobulin
(Santa Cruz Biotechnology, Inc.).
Cell Treatments—Apoptosis was induced in HeLa cells by treatment
with 10 ng/ml tumor necrosis factor- and 10 g/ml cycloheximide for
3–6 h and in Jurkat cells with 50 M etoposide for 2–6 h. Some
cells were pretreated for 2 h with the caspase inhibitor Ac-DEVD-CHO
(Calbiochem) or benzyloxycarbonyl-Val-Ala-Asp(OMe)-fluoromethyl
ketone (Z-VAD-fmk; BIOMOLResearch Labs Inc.) at 10M.Cells were
collected by trypsinization and centrifugation and washed and lysed in
SDS loading buffer. Protein concentrationswere determined using aDC
protein assay kit (Bio-Rad), and proteins were analyzed by SDS-PAGE
and Western blotting.
Cell Extracts—Human nuclear and cytosolic S100 extracts, prepared
from exponentially growing HeLa cells by the method of Dignam et al.
(33), were purchased from CilBiotech S. A. (Mons, Belgium). S100
extracts were supplied in 20 mM Hepes (pH 7.5), 10 mM KCl, 10 mM
MgCl2, and 0.5 mM dithiothreitol. Nuclear extracts were supplied in
HeLa nuclear extract buffer (20 mM Hepes (pH 7.9), 20% (v/v) glycerol,
0.1MKCl, 0.2mMEDTA, 0.5mMphenylmethylsulfonyl fluoride, and 0.5
mM dithiothreitol). Extracts, which were supplied frozen, were thawed
on ice, aliquoted, snap-frozen, and stored in liquid nitrogen. Protein
concentrations were 10 mg/ml for S100 extract and 20 mg/ml for
nuclear extract as determined using the DC protein assay kit. Xenopus
egg extracts were prepared as described previously (34).
Caspase Activation in Cell Extracts—Caspases were activated in
HeLa S100, mixed S100/nuclear, and Xenopus egg extracts supple-
mented with 1 mM ATP, 10 ng/l creatine kinase, and 5 mM creatine
phosphate (Sigma) by incubation at 30 °C with 5 M cytochrome c.
Caspase-3/7 activation was monitored by cleavage of the fluorogenic
peptide Ac-DEVD-7-amido-4-methylcoumarin (35). When used, Ac-
DEVD-CHO or Z-VAD-fmk (10 M) was preincubated in extracts for
1 h prior to the addition of cytochrome c. 35S-Labeled Claspin proteins
were added in 0.02 l of in vitro translation product/l of extract.
Phosphorylation of Claspin and Chk1 in Cell Extracts—Amixture of
equal volumes of HeLa nuclear and cytosolic S100 extracts was incu-
bated for 30 min at 30 °C in the presence of 50 ng/l (dA)70(dT)70
(synthesized by MWG Biotech and annealed as described previously
(36)), 10M okadaic acid (BIOMOL Research Labs Inc.), 1 mMATP, 10
ng/l creatine kinase, 5 mM creatine phosphate, and 0.02 l of in vitro
translation product/l of extract. For each sample, 75g of protein was
run on a 12% polyacrylamide gel and analyzed by Western blotting or
autoradiography. 3-Biotinylated (dA)70 and 5-biotinylated (dT)70
(MWG Biotech) were annealed with untagged (dT)70 and (dA)70,
respectively, as described (36) to generate 3-biotinylated (dA)70(dT)70
and 5-biotinylated (dA)70(dT)70.
Immunoprecipitation of Chk1—Chk1 was phosphorylated in 600 g
of extract as described above with the addition of 2 l of in vitro trans-
lated Claspin and then immunoprecipitated for 1 h at 4 °C using sheep
anti-Chk1 or control sheep anti-Xenopus Mog1 antibody prebound in
the presence of 2% (w/v) bovine serumalbumin to proteinG-Dynabeads
(Dynal Biotech). Beads were isolated using a Dynal magnetic particle
concentrator and washed once with HeLa nuclear extract buffer; twice
with 10 mM Hepes (pH 7.5), 150 mM NaCl, 0.1% (v/v) CHAPS, 2.5 mM
EGTA, and 20 mM -glycerol phosphate; and once with 10 mM Hepes
(pH 7.5) and 150 mMNaCl. Proteins were boiled off the beads into SDS
loading buffer and analyzed by Western blotting with mouse mono-
clonal anti-Chk1 antibody or by autoradiography.
DNA Precipitation Assay—Chk1 was phosphorylated in 600 g of
extract as described above using either non-biotinylated or biotinylated
(dA)70(dT)70 with the addition of 3 l of in vitro translated Claspin (or
truncated). Particulate material was removed by centrifugation for 1
min in a bench-top centrifuge, and the supernatant was incubated with
30 l of M-280 streptavidin-Dynabeads (Dynal Biotech) for 2 h at 4 °C.
Beads were collected through a 1 M sucrose cushion (0.5 ml) by centrif-
ugation at 6000 g for 5 min and washed twice with 10 mMHepes (pH
7.6), 80mMNaCl, 0.1%Nonidet P-40, 2.5mMEGTA, and 20mM-glyc-
erol phosphate. The beads were collected using the Dynal magnetic
particle concentrator. Proteins were boiled off the beads into SDS load-
ing buffer and analyzed by autoradiography.
Immunodepletion of Caspases—Approximately 1 mg of cell extract
was subjected to three rounds of depletion (1 h each at 4 °C) with1.5
g of specific antibody prebound to beads coated with protein A (rabbit
antibodies) or protein G (goat polyclonal or mouse monoclonal anti-
bodies). Samples were used to confirm depletions by Western blotting
with antibodies raised in different species from the immunoprecipitat-
ing antibodies.
3 The abbreviations used are: PARP, poly(ADP-ribose) polymerase; Z-VAD-fmk, benz-
yloxycarbonyl-Val-Ala-Asp(OMe)-fluoromethyl ketone; CHAPS, 3-[(3-cholamidopro-
pyl)dimethylammonio]-1-propanesulfonic acid.
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Cleavage of Claspin by Caspase-7—Purified active recombinant
human caspase-7 (Pharmingen) was diluted in 20 l of 50 mM Hepes-
KOH (pH 7.5), 50 mM KCl, and 10 mM EDTA with 1 l of in vitro
translated wild-type or mutant Claspin (C terminus) and incubated at
30 °C for 2 h.
RESULTS
Claspin Is Cleaved by a Caspase during Apoptosis—Human Claspin
has a predicted molecular mass of 151 kDa, but migrates anomalously
on SDS-polyacrylamide gel with an apparent molecular mass of 250
kDa as noted previously (26). In a human cell-free system made from a
mixture of nuclear and cytoplasmic extracts of HeLa cells (29) in which
caspases are activated by the addition of cytochrome c (35), Claspin was
modified from the apparent 250-kDa form to a doubletwith an apparent
molecular mass of 220 kDa, suggesting that it was being proteolyti-
cally cleaved (Fig. 1A). Claspin cleavage followed processing of
caspase-7 (Fig. 1A), which is associated with activation of this aspartyl
protease and cleavage of PARP, a substrate for caspase-7 and caspase-3
(37). Cleavage of Claspin, PARP, and caspase-7 in this system was com-
pletely blocked by the tetrapeptide caspase inhibitors Ac-DEVD-CHO
and Z-VAD-fmk (Fig. 1B), confirming that cleavage of Claspin, like
PARP, was due to caspase activity.
In HeLa cells in which apoptosis was induced by a combination of
tumor necrosis factor- and cycloheximide, Claspin was similarly pro-
cessed from the 250-kDa form to the220-kDa form after 6 h of incu-
bation, when PARP cleavage and caspase-7 activation were also appar-
ent (Fig. 1C). An antibody raised against a peptide derived from the
C-terminal region of Claspin detected a polypeptide that migrated at
30 kDa, consistent with the generation of a smaller C-terminal frag-
ment. As in the cell-free system, processing of Claspin, PARP, and
caspase-7 was inhibited by Ac-DEVD-CHO. In addition to apoptotic
cleavage, the total amount of Claspin declined substantially following
treatment with tumor necrosis factor- and cycloheximide, and this
loss was not prevented by Ac-DEVD-CHO. This indicates that there is
also a caspase-independent pathway for the degradation of Claspin in
cells.
Claspin Cleavage Coincides with Inactivation of Checkpoint Sig-
naling—When Jurkat cells were treated with the topoisomerase II
poison etoposide, which induces DNA damage through generation
of double-strand breaks, there was an initial strong activation of the
Chk1 pathway. This activation was evident from the strong induc-
tion of phosphorylation of Chk1 at Ser345, a site targeted by ATR (7),
together with the appearance of a slower migrating form of Claspin,
most likely due to its phosphorylation (Fig. 1D). However, after 4–6
h of treatment with etoposide, caspase-7 was activated, PARP was
cleaved, and the level of full-length Claspin was greatly reduced.
Although the appearance of a large fragment of Claspin was not
observed in these cells, the loss of Claspin was prevented by the
caspase inhibitor Z-VAD-fmk, confirming that it was due to caspase
activity. It was notable that the caspase-dependent loss of Claspin
after prolonged incubation coincided with dephosphorylation of
Chk1. In contrast, the level of Chk1 was only slightly diminished
after 6 h of treatment with etoposide, and the level of ATR, which is
not cleaved by caspases (38), was stable. Dephosphorylation of Chk1
was also inhibited by Z-VAD-fmk. These results suggest that
caspase-mediated cleavage of Claspin inactivates cell cycle check-
point signaling from damaged DNA via ATR to Chk1.
Claspin Is Cleaved by a Caspase at a Single Site—Because cleavage of
Claspin produced a large fragment with an apparent molecular mass of
220 kDa and a smaller C-terminal fragment of 30 kDa, a major site of
cleavage is likely to reside within the C-terminal half of the protein.
FIGURE 1. Human Claspin is cleaved by a
caspase during apoptosis. A, cleavage of Claspin
in a cell-free system. Caspase activation was
induced in a system made from equal volumes of
HeLa cytosolic (S100) andnuclear extracts by incu-
bationwith cytochrome c. B, cleavage of Claspin in
a cell-free system is blocked by caspase inhibitors.
HeLa extracts were incubated with cytochrome c
(cyt c) and either Ac-DEVD-CHO (D) or Z-VAD-fmk
(Z) as indicated. Samples removed at the start of
the incubation or after 8 hwere analyzed byWest-
ern blotting with antibody to Claspin, PARP,
caspase-7, or Chk1. C, caspase-dependent cleav-
ageof Claspin inHeLa cells. Cellswere treatedwith
tumor necrosis factor- (TNF) and cycloheximide
(CHX) together with Ac-DEVD-CHO as shown. D,
caspase-dependent cleavage of Claspin in Jurkat
cells. Cells were treated with etoposide with or
without 10 M Z-VAD-fmk for the times shown. In
each experiment, sampleswere removed after the
times shown and were analyzed by Western blot-
ting with antibody against Claspin, PARP,
caspase-7 (Casp 7), Chk1, the Claspin C-terminal
fragment (ClaspinCT), Chk1 phosphorylated at
Ser345 (pChk1), or ATR as indicated. The migration
positions of Claspin forms with apparent molecu-
lar masses of 250 kDa (p250), 220 kDa (p220), and
30 kDa (p30) are indicated by arrows. Nonspecific
bands reacting with antibody are labeled with an
asterisk.
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Indeed, in vitro transcribed and translated human Claspin-(679–1332),
which migrated on SDS-polyacrylamide gel at 120 kDa, was cleaved to
produce one fragment with an apparent molecular mass of 75 kDa and
a second of 30 kDa in apoptotic extracts of HeLa cells (S100) and Xeno-
pus eggs. In both extracts, Claspin-(679–1332) cleavage was completely
inhibited by Ac-DEVD-CHO (Fig. 2A). Examination of the amino acid
sequence of Claspin-(679–1332) revealed five DXXDmotifs that might
be recognized by the effectors caspase-3 and caspase-7, which are inhib-
ited by Ac-DEVD-CHO. Similar motifs are present in other substrates
for these caspases (Fig. 2B). In these substrates, cleavage occurs after the
second Asp residue, which is essential for recognition by the caspase.
We therefore mutated the five Asp residues in Claspin-(679–1332) at
which cleavage might occur to Ala and found that mutation of only
Asp1072 prevented caspase cleavage (Fig. 2C). Comparison of Claspin-
(679–1332) with full-length Claspin and Claspin-(1–678) demon-
strated that Asp1072 was the only site at which cleavage occurred.
Indeed, the fragments predicted to be generated by caspase cleavage of
the full-length protein, Claspin-(1–1072) and Claspin-(1073–1332),
were stable against caspase activity in apoptotic cell extracts (Fig. 2D).
The doublet formed during cleavage of the endogenous protein in cell
extracts (Fig. 1A) may therefore be due to another post-translational
modification of a fraction of Claspin molecules. Comparison of the
amino acid sequences of Claspin from different species indicated that
the site of cleavage in human Claspin is conserved in mouse, but not in
Xenopus, although a number of Asp residues are present within this
region of the Xenopus protein. In Drosophila Claspin, there is a DEYD
motif within this region of the protein that is a potential caspase cleav-
age site (Fig. 2E).
Claspin Is Cleaved Specifically by Caspase-7—Cleavage of human
Claspin after aDEYDmotif suggests that it is a substrate for caspase-3 or
caspase-7, both of which show a strong preference for sites with aspar-
tate at the P4 position and glutamate at the P3 position (39). To deter-
mine whether one or the other of these caspases is required for Claspin
cleavage, we depleted them from HeLa cell extracts using specific anti-
bodies (Fig. 3A). Depletion of caspase-3 only slightly reduced cleavage of
Claspin-(679–1332) in response to cytochrome c, whereas depletion of
caspase-7 strongly inhibited cleavage. Depletion of caspase-9, which is
required for activation of caspase-3 and caspase-7 in response to cyto-
chrome c (40), completely inhibited Claspin-(679–1332) cleavage. In
contrast, depletion of caspase-8 had no effect on Claspin-(679–1332)
cleavage. This indicates that Claspin is cleaved at Asp1072 predomi-
nantly by caspase-7 downstream of caspase-9. Claspin-(679–1332) was
indeed cleaved into two fragments by active caspase-7 (Fig. 3B), and this
processing was completely inhibited by mutation of Asp1072 to Ala
(D1072A). Active caspase-3was also capable of cleavingClaspin directly
at this site (data not shown), although caspase-3 was clearly less impor-
tant than caspase-7 in cell extracts (Fig. 3A).
Cleavage of ClaspinDoesNot Prevent Its Phosphorylation in aHuman
Cell-free System—Claspin is phosphorylated in response to DNA dam-
age or replication arrest, and this controls the interaction of Claspin
FIGURE 2. Human Claspin is cleaved by a
caspase at a single site, Asp1072. A, cleavage of
Claspin in apoptotic cell extracts. Claspin-(679–
1332) was incubated with HeLa cytosolic extract
(S100) or Xenopus egg extract (XEE) in which
caspases were activated by cytochrome c. The
caspase inhibitor Ac-DEVD-CHO was added as
indicated. B, comparison of caspase-3/7 cleavage
sites in some substrates and putative sites in
Claspin-(679–1332). PKC, protein kinase C. C,
cleavage of Claspin requires Asp1072. Claspin-
(679–1332) proteins with single Asp residues
changed to Ala were incubated in apoptotic HeLa
cytosolic extract. D, Claspin is cleaved at a single
site, Asp1072. Full-length Claspin or truncated pro-
teins containing the amino acids indicated were
incubated in apoptotic HeLa cytosolic extractwith
or without Ac-DEVD-CHO. E, comparison of amino
acid sequences of Claspin from different species
with amino acids 1063–1085 of human Claspin.
Conserved amino acids are shaded; the putative
caspase recognition motif is underlined; and the
caspase cleavage site in human Claspin is indi-
cated by an arrow. In the experiments shown in A,
C, and D, in vitro translated 35S-labeled Claspin
proteins were incubated in extracts at 30 °C for 9 h
with the addition of cytochrome c to activate
caspases. Samples were analyzed by SDS-PAGE
and autoradiography. The migration positions of
molecularmassmarkers (in kilodaltons) are shown
on the left.
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with other proteins involved in the checkpoint signaling pathway. Phos-
phorylation of two sites in human Claspin, Thr916 and Ser945, forms a
Chk1-binding motif that is conserved with respect to Xenopus Claspin
(28, 29). Cleavage of Claspin by caspase-7 could potentially regulate the
phosphorylation ofClaspin and thereby affect its function.We therefore
examined the phosphorylation of Claspin-(679–1332) and the frag-
ments generated by caspase-7 cleavage, Claspin-(679–1072) and
Claspin-(1073–1332), in response to activation of the checkpoint path-
way in a human cell-free system (29) inwhich the checkpoint pathway is
activated by an oligonucleotide duplex made of annealed (dA)70 and
(dT)70 together with the protein-serine/threonine phosphatase inhibi-
tor okadaic acid. Like Claspin-(679–1332), Claspin-(679–1072) was
phosphorylated at multiple sites in the presence of okadaic acid, and
phosphorylation was enhanced by (dA)70(dT)70, showing that the
majority of phosphorylation sites within the C-terminal region of
Claspin reside in fragment 679–1072 and that this phosphorylation
does not appear to be affected by removal of the C-terminal 260 amino
acids. Phosphorylation of Claspin-(679–1072) andClaspin-(679–1332)
was partially inhibited by caffeine, which inhibits ATR (15, 41), and was
strongly but not completely blocked by staurosporine and Ro 31-8220,
which inhibit several protein kinases (42). Claspin-(1073–1332) was
only partially up-shifted to a single band in response to okadaic acid/
(dA)70(dT)70, but this result nevertheless indicates that at least one
previously unidentified phosphorylation site exists with the C-terminal
260 amino acids.
Cleavage of Claspin Separates Its Chk1-bindingDomain from aDNA-
interacting Domain—To test whether Claspin cleavage at Asp1072
affects the interaction with Chk1, we determined the interaction
between Chk1 and fragments of Claspin in human cell extracts. As
found previously (29), the non-phosphorylated form of Claspin is a
sticky protein that precipitates nonspecifically with beads, and Claspin-
(679–1332) and Claspin-(679–1072) showed similar characteristics
(Fig. 4B). However, in the presence of (dA)70(dT)70 and okadaic acid,
phosphorylated Claspin-(679–1332) and Claspin-(679–1072) precipi-
FIGURE 3. Claspin is cleaved by caspase-7. A,
Claspin cleavage requires caspase-7. HeLa cytoso-
lic extract was immunodepleted with antibodies
against caspase (Casp)-3, -7, -9, and -8, whichwere
immunoprecipitated (IP) using protein A- or pro-
tein G-coupled beads. Mock depletions were per-
formed with protein A (Pr A)- or protein G (Pr
G)-coupled beads alone. In each case, specific
depletion was confirmed by SDS-PAGE and West-
ern blotting (WB) with anti-caspase antibodies
(lower panels). Depleted extracts were incubated
with 35S-labeled Claspin-(679–1332), and cyto-
chrome c was added to activate the caspases.
Claspinprocessingwas assessedbySDS-PAGEand
autoradiography. B, Claspin is cleaved at Asp1072
by caspase-7. In vitro translated 35S-labeled
Claspin-(679–1332) and mutant D1072A were
incubated with varying amounts of caspase-7 for
2 h at 30 °C, and then samples were analyzed by
SDS-PAGE and autoradiography. WT, wild-type
Claspin.
Cleavage of Claspin by Caspase-7
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tated specificallywithChk1,whereasClaspin-(1073–1332) did not. This
result is consistent with separation by caspase-7 cleavage of the C-ter-
minal 260 amino acids from the Chk1-binding motif in residues 679–
1072, which contain phosphorylation sites at Thr916 and Ser945.
To examine the possible interaction betweenClaspin and the double-
stranded oligonucleotide, we used (dA)70(dT)70 duplexes labeled with a
biotin group at either the 5-end of the (dT)70 strand or the 3-end of the
(dA)70 strand. We found that the 3-biotinylated duplex was less effec-
tive than either the 5-biotinylated or non-biotinylated duplex in induc-
ing phosphorylation of Claspin-(679–1332) in cell extracts. Full-length
Claspin was precipitated from extracts when the 5-biotinylated duplex
was retrieved on streptavidin-coupled beads, but was not precipitated
from extracts incubated with the non-biotinylated duplex (Fig. 5A).
Removal of residues 1073–1332 completely abolished the interaction of
FIGURE 4.Phosphorylation of Claspin and inter-
action with Chk1. A, phosphorylation of Claspin
fragments in a human cell-free system. In vitro
translated 35S-labeled Claspin-(679–1332), Claspin-
(679–1072), and Claspin-(1073–1332) (C-terminal
fragment (CTF)) were incubated for 30min at 30 °C
in a mixture of HeLa cytosolic (S100) and nuclear
extracts supplementedwith 50ng/l (dA)70(dT)70
(poly(dA/dT)70), 10M okadaic acid (OA), 5 mM caf-
feine (caff), 5 M staurosporine (stau), or 20 M Ro
31-8220 (Ro) as indicated. Samples were analyzed
by SDS-PAGE and autoradiography. B, interaction
ofChk1withphosphorylatedClaspin. In vitro trans-
lated 35S-labeled Claspin-(679–1332), Claspin-(679–
1072), and Claspin-(1073–1332) were incubated
for 30 min at 30 °C in a mixture of HeLa cytosolic
(S100) and nuclear extracts supplementedwith 50
ng/l (dA)70(dT)70 and 10M okadaic acid as indi-
cated. Immunoprecipitations with anti-Chk1
(Chk1 IP) or control sheep (Control IP) antibody
were carried out, and bound proteins were ana-
lyzedbyblotting for Chk1withmousemonoclonal
anti-Chk1 antibody or by autoradiography for
Claspin proteins.
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Claspin with the 5-biotinylated duplex, whereas Claspin-(1073–1332)
did interact (Fig. 5B). This demonstrates that the interaction of Claspin
with (dA)70(dT)70 requires the C-terminal 260 amino acids that are
separated from the Chk1-binding domain through cleavage by
caspase-7. To test whether this C-terminal DNA-interacting domain
might have a dominant effect on downstream signaling to Chk1, we
added recombinant Claspin-(1073–1332) to extracts and found that
there was a dose-dependent inhibition of Chk1 phosphorylation
detected by mobility on SDS-polyacrylamide gel and specifically at
Ser345, a site targeted by ATR, using a site-specific antibody (Fig. 5C).
Thus, cleavage of Claspin by caspase-7 not only separates the Chk1- and
DNA-binding domains of Claspin, but also generates a competitive
inhibitor of Chk1 phosphorylation.
DISCUSSION
Claspin plays a critical role in activation of the Chk1 protein kinase in
response to incomplete DNA replication and DNA damage. In this
study, we have shown that, during apoptosis, Claspin is targeted for
cleavage by caspase-7 after a single residue, Asp1072. Using a human
cell-free system in which the Chk1 pathway is activated by double-
stranded oligonucleotides, we have shown that this cleavage separates
the Chk1-binding motif in Claspin from a C-terminal domain that is
required for interaction with DNA (Fig. 6A). The released C-terminal
fragment prevents the phosphorylation of Chk1 associated with its acti-
vation and thereby blocks checkpoint signaling through the Chk1
pathway.
Inactivation of Claspin by caspase-7-mediated cleavage may play an
important role in switching the response of a cell from cell cycle arrest,
an initial response that provides an opportunity for damage repair and
cell survival, to induction of cell death following prolonged arrest of
DNA replication or the persistence of DNA damage. In this model (Fig.
6B), activation ofATR andChk1 is an acute response toDNAdamage or
ongoing replication that provides a protectivemechanism for the cell by
arresting cell cycle progression and by permitting DNA damage to be
repaired or DNA replication to be completed. A survival role of the
ATR/Claspin/Chk1 pathway is supported by the sensitization of cells
lacking one of these proteins to DNA damage (11, 12, 14, 20). Although
this role might be an indirect one, due to functions in restraining cell
cycle progression and perhaps initiating damage repair, it remains pos-
sible that the ATR/Claspin/Chk1 pathway also controls apoptosis more
directly. With prolonged arrest, additional responses, in part through
transcription controlled by activation of p53 (43), induce apoptotic
pathways that cause activation of caspase-7, resulting in cleavage of
Claspin and inactivation of the checkpoint. This may relieve a direct
inhibitory effect on apoptosis or cause unrestrained progression
through a critical cell cycle transition and indirect activation of apopto-
sis through mechanisms that detect the presence of genomic damage
during such transitions or in a subsequent cell cycle phase.
The specific role for caspase-7 in the cleavage of Claspin is unusual.
Caspase-7 and the closely related enzyme caspase-3 have very similar
primary substrate recognition requirements, both targeting DXXD
motifs (39). Caspase-3 is the predominant activity in most cells toward
substrates containing suchmotifs (44), although caspase-7 can compen-
sate for the loss of caspase-3 to some extent, e.g. inMCF-7 cells (45) and
in caspase-3/ mouse cells (46, 47). A distinct biological role for
caspase-7 is indicated by the apparent lethality of gene knockout inmice
(48). Caspase-7 has been reported to cleave PARP (37), but cleavage of
this substrate can take place in the absence of caspase-7, suggesting that
caspase-3 can also perform this function (49). In the case of Claspin,
although purified caspase-7 and caspase-3 can both cleave the protein at
the DEYD1072 motif (Fig. 3 and data not shown), when cleavage is ana-
lyzed under near physiological conditions in concentrated cell extracts,
caspase-7 is clearly the predominant activity.
A distinct, early role for caspase-7 inDNAdamage-induced apoptosis
has been indicated by experiments in which deletion of caspase-7 in
chicken DT40 cells delayed activation of caspase-3 and caspase-6 after
treatment with etoposide (49). Interestingly, active caspase-7 has been
reported to be present in the nucleus (37, 50), where it could act on
FIGURE 5.Caspase-mediated cleavageof Claspin separates a C-terminal DNA-inter-
acting domain from the Chk1-binding domain. A, interaction of Claspin with double-
stranded oligonucleotides. In vitro translated 35S-labeled Claspin-(679–1332) was incu-
bated for 30 min at 30 °C in a mixture of HeLa cytosolic (S100) and nuclear extracts
supplemented with 10 M okadaic acid (OA) and 50 ng/l (dA)70(dT)70 (poly(dA/dT)70),
either non-biotinylated or biotinylated at the 5- or 3-end of the poly(dA) strand as
indicated. Proteins precipitated with streptavidin beads or in the total extract were ana-
lyzed by SDS-PAGE and autoradiography. B, interaction of Claspinwith double-stranded
oligonucleotides requires a C-terminal domain. Extractwas incubatedwith in vitro trans-
lated 35S-labeled full-length Claspin, its large N-terminal fragment (NTF; amino acids
1–1072), or its smaller C-terminal fragment (CTF; amino acids 1073–1332) together with
okadaic acid and (dA)70(dT)70, either non-biotinylated or 5-biotinylated. Proteins in the
total extract or bound to streptavidin beads were analyzed by SDS-PAGE and autora-
diography. C, inhibition of Chk1 phosphorylation by Claspin-(1073–1332). HeLa extract
was incubated for 30 min at 30 °C with okadaic acid plus (dA)70(dT)70 and, at the con-
centrations shown, the His6-tagged C-terminal fragment (Claspin-(1073–1332)) or His6-
C287A, an inactive caspase-9 mutant, as a control (Ctrl). Samples were analyzed by SDS-
PAGE and Western blotting with anti-Chk1 and anti-phospho-Ser345 Chk1 antibodies.
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nuclear substrates such as Claspin. Furthermore, experiments inmouse
cells lacking the caspase-9 activator Apaf-1 have suggested that
caspase-7 can be activated by amechanism distinct from themitochon-
drial Apaf-1/caspase-9/caspase-3 pathway (51). Such amechanism acti-
vating caspase-7 in the nucleus in response to DNA damage or DNA
replication arrest might be particularly important in the initial induc-
tion of Claspin cleavage and inactivation of the Chk1 pathway. With
further, prolongedDNAdamage, increased expression of pro-apoptotic
BH3 (Bcl-2 homology 3) domain-containing proteins such as Puma and
Noxa through activation of p53 (43) would cause further activation of
caspase-7 as well as caspase-3 by the mitochondrial pathway acting on
Apaf-1/caspase-9.
Our results indicate that cleavage of Claspin by caspase-7 effectively
inactivates the protein by separating the Chk1-binding domain from a
C-terminal domain that is required for interaction with DNA and the
phosphorylation and activation of Chk1 by ATR. A number of other
proteins involved in responses to DNA damage, including PARP (52),
ATM (38), and DNA-dependent protein kinase (53–56), are also inac-
tivated by caspase cleavage during apoptosis by separation of functional
domains. Previous work has identified a putative DNA-bindingmotif in
the N-terminal half of Claspin that is conserved in yeast Mrc1 (26, 27),
although another, weaker, direct interaction with DNA through the
C-terminal regionwas also found (26). Our results indicate that a region
contained within the C-terminal 260 amino acids of human Claspin is
essential for interaction with DNA in a cell-free system in which the
checkpoint pathway to Chk1 is functional. This interaction may well
involve interaction with other proteins rather than direct binding to
DNA. Surprisingly, such a stable interaction with double-stranded oli-
gonucleotides was not observed in Xenopus egg extracts by Kumagai et
al. (23), possibly because of a more dynamic interaction of Claspin with
DNA molecules in that system. The separation of the C-terminal
domain from the Chk1-binding domain by caspase-7 creates a domi-
nant inhibitor of the pathway that prevents Chk1 phosphorylation asso-
ciatedwith its activation, probably due to the inability to recruit Chk1 to
ATR. However, phosphorylation of Claspin itself does not appear to be
affected by the inability to interact stably with DNA, suggesting that the
relevant kinases do not require assembly of Claspin into a DNA-inter-
acting complex. Our results also indicate that the C-terminal domain
contains at least one phosphorylation site that could regulate the inter-
action of this domain with DNA or other proteins.
In summary, we have identified human Claspin as a substrate for
caspase-7, supporting a distinct role for this caspase in the control of
early events during genotoxic responses. Inactivation of Claspin by
caspase-7 may play a pivotal role in the switch from cell cycle arrest and
restraint of apoptosis to inactivation of the checkpoint and induction of
apoptosis in response to genotoxic damage. The control of Claspin
function through caspase-7-mediated cleavage may play a role in deter-
mining the response of cancer cells to genotoxic therapies.
FIGURE 6. Model of the effect of Claspin cleav-
age by caspase-7. A, caspase-7 (Casp7) cleaves
Claspin after Asp1072, generating a large N-termi-
nal fragment (NTF) containing a Chk1-binding
domain (CKBD) that includes a motif phosphoryl-
ated at two sites, Thr916 and Ser945, and a smaller
C-terminal fragment (CTF) required for association
withDNA. aa, amino acids. B, phosphorylation and
activation of Chk1 by ATR in response to DNA
damage or during DNA replication require recruit-
ment of Chk1 to DNA by Claspin. With prolonged
DNA damage or DNA replication arrest, activation
of caspase-7 results in proteolytic cleavage of
Claspin, dephosphorylation of Chk1, inactivation
of the checkpoint signal, and promotion of apo-
ptosis. Activated forms of Chk1 and ATR are indi-
cated by asterisks.
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